Skip to content

For Immuno-oncology

We empower drug developers to increase the speed of their R&D and the success of their clinical programs by:

  • Elucidating drug candidates’ MoA on a single-cell and multiomics level for mechanistic understanding or comparison with other drugs.
  • Identifying predictive markers of response for patient stratification and improved clinical trial design.
  • Finding predictive markers of toxicity for better patient management.
  • Identifying predictive biomarkers to optimize selection and enrichment of cell therapy products for stronger and more durable response, and to mitigate product toxicity.
  • Co-developing companion diagnostic assays.
Partnering illustration

From Single-Cell Data Generation To Multi-Omics Data Integration To Data Insights

How we create value and engage with our partners

Scailyte strengths

We have identified biomarker signatures for MoA, clinical response and toxicity prediction in industry partnerships

Partner
Indication
Clinical question
Technology
Tissue
#patients
Outcome and Status
COMPANY A
Solid tumors
(tg T cells)
Prediction of therapy response
scRNA-seq
Infusion cell product
14
Correlation of r = 0.75 with measured response
Discovery project
COMPANY B
Refractory rheumatoid arthritis
Treatment mode of action
scRNA-seq
Murine
hind-limbs
20
1.0 AUC
Discovery project
Release Therapeutics (MaxiVAX)
Solid tumors
(cancer vaccine)
Prediction of therapy response and toxicity
FC, IHC, proteomics, etc.
PBMCs, serum, tumor
20
completed
Discovery project
Turnstone Biologics, US
Solid tumors
(TIL therapy)
Prediction of therapy response and toxicity
CITEseq, TCRseq
Infusion cell product, PBMCs
55
ongoing
Discovery project
COMPANY D
Autoimmunity
Prediction of therapy response, toxicity, MoA
CITE-seq, TCR-seq, FC
PBMCs
40
ongoing
Discovery project
COMPANY E
Cell therapy
Prediction of manufacturing success
CITE-seq
PBMCs
24
ongoing
Discovery project

What Our Partners Say About Us

Meghan Verschoor

Meghan Verschoor

Associate Director, Data Science in Clinical and Translational Medicine at Turnstone Biologics

“Our team is very impressed with the level of attention to detail and domain knowledge that the Scailyte team brings to our project. We’re excited to continue working with your team!”
Thomas Mehrling

Thomas Mehrling

MD PhD, CEO of MaxiVAX

“Scailyte has been instrumental in analyzing phase IIa clinical single-arm trial data of our most advanced development program. Scailyte’s scientific expertise, communication style and agility are commendable”
Indication
Clinical question
Technology
Tissue
#patients
Outcome and Status
Sezary Syndrome (CTCL)
Diagnosis of CTCL
CyTOF
PBMCs
60 + 33
0.98 AUC; patent filed (EP19219889)
Flow-cytometry antibody panel prototype
Endometriosis
Diagnosis of endometriosis
scRNA-seq
PBMCs
42 + 60
0.9 AUC; patent filed (EP21204845)
Clinical validation and assay development
scRNA-seq
Endometrium
35 + 30
0.9 AUC; patent filed (EP21204856)
Clinical validation and assay development
Covid19 / ARDS
Prediction of ARDS development in Covid19-patients
CyTOF
PBMCs
Clinical data
37 + 17
0.95 – 1 AUC
Roussel et al., Cell Reports Medicine 2021
Head and neck squamous cell carcinomas (HNSCC) (Radiotoxicity)
Prediction of toxicity
CyTOF
PBMCs Clinical data
41
0.89 AUC for binned toxicity scores
DLBCL (CAR-T Cells)
Prediction of therapy response and toxicity
scRNA-seq
Infusion cell product
23
0.8 AUC efficacy prediction
1 AUC toxicity prediction
Solid tumors
(tg T cells)
Prediction of therapy response
scRNA-seq
Infusion cell product
14
Completed
Service project
Refractory rheumatoid arthritis
Treatment mode of action
scRNA-seq
Murine
hind-limbs
20
Completed
Service project
Solid tumors
(TIL therapy)
Prediction of therapy response and toxicity
CITEseq, TCRseq
Infusion cell product, PBMCs
55
ongoing
Service project
Solid tumors
(cancer vaccine)
Prediction of therapy response and toxicity
FC, IHC, proteomics, etc.
PBMCs, serum, tumor
20
ongoing
Service project
Interested in partnering with us?